Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Delmer

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
The New England Journal of Medicine|December 24, 2010
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemiaClaude Preudhomme, Joëlle Guilhot, Franck Emmanuel Nicolini, et al.
Hemasphere|October 16, 2020
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, et al.
Blood Advances|November 29, 2021
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemiaCristina Bagacean, Rémi Letestu, Chadi Al-Nawakil, et al.
Annals of Hematology|January 26, 2021
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohortFlorian Bouclet, Anne Calleja, Marie-Sarah Dilhuydy, et al.
Leukemia & Lymphoma|January 10, 2019
Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE studyDriss Chaoui, Maya Hacini, Olivier Fitoussi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2023
Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trialLaurence Brugières, Nathalie Cozic, Roch Houot, et al.
The Lancet. Haematology|December 25, 2017
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 studyCaroline Dartigeas, Eric Van Den Neste, Julie Léger, et al.
Radiology|April 15, 2020
Performance of CT Compared with <sup>18</sup>F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin LymphomaFatima-Zohra Mokrane, Aiping Chen, Lawrence H Schwartz, et al.
Haematologica|December 22, 2022
Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)Caroline Algrin, Louis Pérol, Elise Chapiro, et al.
Leukemia & Lymphoma|July 4, 2015
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemiaCaroline Dartigeas, Eric Van Den Neste, Christian Berthou, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
The New England Journal of Medicine|December 24, 2010
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemiaClaude Preudhomme, Joëlle Guilhot, Franck Emmanuel Nicolini, et al.
Hemasphere|October 16, 2020
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, et al.
Blood Advances|November 29, 2021
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemiaCristina Bagacean, Rémi Letestu, Chadi Al-Nawakil, et al.
Annals of Hematology|January 26, 2021
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohortFlorian Bouclet, Anne Calleja, Marie-Sarah Dilhuydy, et al.
Leukemia & Lymphoma|January 10, 2019
Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE studyDriss Chaoui, Maya Hacini, Olivier Fitoussi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2023
Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trialLaurence Brugières, Nathalie Cozic, Roch Houot, et al.
The Lancet. Haematology|December 25, 2017
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 studyCaroline Dartigeas, Eric Van Den Neste, Julie Léger, et al.
Radiology|April 15, 2020
Performance of CT Compared with <sup>18</sup>F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin LymphomaFatima-Zohra Mokrane, Aiping Chen, Lawrence H Schwartz, et al.
Haematologica|December 22, 2022
Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)Caroline Algrin, Louis Pérol, Elise Chapiro, et al.
Leukemia & Lymphoma|July 4, 2015
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemiaCaroline Dartigeas, Eric Van Den Neste, Christian Berthou, et al.
Pageof 11